External Review for GLP-1 Insurance Denial: What to File After Your Appeal Is Denied
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers. Last verified: . 14 min read. This is educational insurance-help content — not medical or legal advice. Your plan documents and your denial letter control your case.
If your insurance denied your GLP-1 — Wegovy, Zepbound, Ozempic, Mounjaro, or another — and said no again after you appealed, external review for a GLP-1 insurance denial is your next move, and it's free to you. An external review hands your case to an independent medical reviewer — an outside expert who does not work for your insurer — and the plan has to follow the decision. It works best when your denial is about medical judgment: the plan says you don't qualify, but your records say otherwise. It's not a guaranteed win, and it won't override a clean coverage exclusion. But the cases below prove it overturns GLP-1 denials all the time — for people who sent the right proof.
Here's what almost nobody tells you: this right barely gets used. In 2024, people on HealthCare.gov appealed fewer than 1% of roughly 85 million denied in-network claims ( KFF). And in a 2023 KFF survey, only about 40% of people even believed they had a right to appeal to a government agency or an independent expert. Yet where the outcomes are public — California reversed about 73% of independent medical reviews in 2023 — the numbers favor people who file.
Not sure if your denial is even worth fighting? Tell us your denial reason, plan type, and state, and we'll show your deadline, where to file, and what to gather first.
Check my external-review deadline →Free, about 60 seconds, no account neededQuick answer: is external review worth filing for your denial?
Find your situation below. Then read the section that matches — that's where the real instructions are.
| Your denial says… | Worth filing external review? | Your first move |
|---|---|---|
| “Not medically necessary” / “doesn't meet criteria” | Usually yes | Get the written criteria, then answer each one with proof |
| “Missing documentation” | Maybe | Ask for the missing-item list, fix the file, and re-submit or appeal first |
| “Step therapy required” (try a cheaper drug first) | Often yes | Document the failure, the side effect, or a real reason it's unsafe for you |
| “Non-formulary” (drug not on the covered list) | Sometimes | Ask for a formulary exception before or alongside your appeal |
| “Weight-loss drugs are excluded” | Usually no | Check if a covered diagnosis applies, or talk to HR |
| “Coverage stopped after you were already on it” | Depends | Compare your old approval to the current rules |
| “Waiting would harm your health” (urgent) | Maybe expedited | Ask your doctor for an urgency letter — a decision can come in 72 hours |
Source: HealthCare.gov; CMS; California DMHC. Deadlines and rules vary by plan and state — your denial letter is the final word.
Free tool: GLP-1 External Review Deadline & Packet Builder
Most people lose on two things: the wrong denial type and a missed deadline. This tool fixes both. Enter your denial reason, plan type, state, and denial dates, and you'll get your filing deadline, where to file, a packet checklist matched to your exact denial, and a doctor-letter prompt you can copy and send.
GLP-1 External Review Deadline + Packet Builder
Free tool. Enter your situation and get your deadline, where to file, and your packet checklist.
What does external review for a GLP-1 insurance denial actually mean?
External review is the step after your insurer turns down your appeal. An independent outside expert — not your insurance company — reviews the denial and makes a decision the plan must follow. Under the Affordable Care Act, most health plans have to offer it, and it's free to you.
Think of it as a path with clear stops:
Denial → internal appeal → final denial → external review → independent decision → if you win, the plan must cover it.
- 1The denial. Your insurer (or its pharmacy reviewer) says no and mails a letter with the reason.
- 2The internal appeal. You ask the insurer to look again, with proof. Federal rules give you at least 180 days from the denial to file this.
- 3The final denial. If the insurer still says no, that's your final internal denial.
- 4The external review. An Independent Review Organization (IRO -- a company of medical experts with no financial tie to your insurer) decides. Their answer is binding on the plan.
A few things people don't realize:
- •The reviewer is a qualified outside expert. For a medical-necessity fight, that is usually a doctor in the right specialty — not the insurer's staff who denied you the first time.
- •It's free to you. There is normally no charge to file.
- •Urgent cases can skip the line. If waiting would seriously hurt your health, you can often ask for an expedited external review at the same time as your internal appeal.
- •If your insurer breaks its own rules — like blowing past its deadlines — you may be allowed to go straight to external review. (The legal term is deemed exhaustion.)
Source: HealthCare.gov, “External Review”; CMS, “HHS-Administered Federal External Review Process”; 45 CFR §147.136.
Want this translated for your exact letter?
Decode my denial reason →What kind of GLP-1 denial did you get? (This decides everything.)
The exact words on your letter control your whole strategy. Pull your Explanation of Benefits (EOB) or your final appeal letter, find the exact reason, and match it below. This is the GLP-1 External Review Fit Matrix.
| What the letter says | What it usually means | ER odds | Proof that actually wins | Smartest next step |
|---|---|---|---|---|
| “Not medically necessary” | The plan covers the drug in general but says your chart didn't prove you qualify | High | The plan's written rules, BMI history, diagnosis codes, other conditions, past medications, proof of a diet/exercise program, a doctor's letter matched line-by-line to each rule | File external review once your internal appeal is final |
| “Missing documentation” | The request was probably denied because the insurer didn't get enough proof | Medium | The denial letter, the original request, chart notes, labs, program logs, pharmacy history | Fix the file and re-submit or appeal first; external review comes after |
| “Step therapy required” | The plan wants you to try a cheaper or older drug first | Medium-high | Dates you tried it, side effects, a real reason it's unsafe for you, your doctor's explanation | Ask for the written step-therapy rule and have your doctor answer it directly |
| “Non-formulary” / “not preferred” | The drug isn't on the plan's covered list | Medium | The formulary, your history with the covered option, your doctor's reasoning | Ask for a formulary exception before or with your appeal |
| “Weight-loss drugs are excluded” | The plan chose not to cover anti-obesity drugs at all | Low | Plan documents, your diagnosis, an FDA-approved use beyond weight loss, proof of any process error | Check for a covered diagnosis or go to HR — don't burn weeks on a fight you can't win |
| “Coverage stopped after prior approval” | The plan changed its rules, or says you no longer meet continuation criteria | Medium-high | Old approval letters, fill history, weight/BMI over time, current continuation rules, a doctor's note on the risk of stopping | File if they misapplied the rules; go to HR if the benefit was removed |
| “Experimental / investigational” | The plan calls the use unproven | High (FDA-approved drugs) | The FDA label, your diagnosis, medical guidelines, your doctor's reasoning | Use this only for an FDA-approved drug and an approved or clearly supported use |
Sources: HealthCare.gov; CMS; U.S. Department of Labor (claims rules); KFF. Denial types cross-checked against payer and provider guidance.
What to ask your insurer for (call the number on your card):
The exact denial reason and code, the specific plan rule they used, the clinical criteria or policy, the formulary-exception process, the external-review instructions, your deadline, and your full prior authorization and appeal file. By law, many health-plan denial notices must identify your claim, the denial reason, the plan standard used, and your appeal and external-review options.
What to ask your doctor for:
A letter of medical necessity that answers the exact denial reason — not a generic letter. A targeted letter is the single biggest difference between the cases that win and the ones that don't.
Not sure which row is yours? We'll classify your denial and tell you if external review is your best shot — or if there's a faster path.
Find out if my denial is worth external review →The honest part: when external review can't win
We're not going to pretend external review is magic, because that would waste your time and your deadline.
Here's the wall: if your plan has a clean exclusion for all weight-loss medications, an external reviewer usually can't force the plan to cover something it never agreed to cover. A reviewer can even agree the drug is right for you — and still uphold the denial, because the exclusion is a coverage decision your employer made, not a medical one.
So if your letter says weight-loss drugs are excluded, external review is probably not your best move. HR, a covered diagnosis, or a cash-pay route may be — and we'd rather send you there than watch you lose your last appeal. (Jump to the exclusion section.)
Now the hopeful part, and it's bigger than the wall. A clean exclusion is just one of the denial types in the matrix above — and most GLP-1 denials aren't that. They're “not medically necessary,” step therapy, continuation, documentation, or “experimental” denials. Those are exactly what external review is built to overturn, and the real cases below prove reviewers overturn them all the time. The biggest reason people lose isn't that their case was hopeless — it's that fewer than 1 in 100 denials ever gets appealed at all ( KFF). So before you assume you're stuck: read your letter.
Is your denial a true exclusion, or something you can actually win?
Check whether this is a denial or a plan exclusion →What's the deadline for a GLP-1 external review?
Move now — the clock is the one thing you can't get back. Under federal rules, you generally have 4 months after you receive your final denial notice to request external review. A standard decision is due within 45 days, and an urgent (expedited) decision can come within 72 hours. Your state may give you more or less time, so your denial letter is the source of truth.
Here's the timeline, with California as a real example of how a state can differ:
| Rule | Federal (ACA) | California (example) |
|---|---|---|
| Internal appeal deadline | File within 180 days of the denial | Follows your plan's notice |
| External review deadline | Within 4 months of the final denial | Within 6 months of the appeal-decision notice |
| Standard decision | Within 45 days | Within 30 days |
| Urgent / expedited decision | Within 72 hours | Within 7 days (faster if life is at risk) |
| Cost to file | Free | Free |
| If you win | Binding on the plan | Plan must authorize within 5 business days |
Source: HealthCare.gov; CMS; California DMHC.
Three deadline rules that save people:
- •Don't wait the full 4 months. Gathering records takes time. Start today.
- •If it's urgent, say so. A doctor's note that a delay would seriously threaten your health can trigger an expedited review.
- •If your insurer is stalling past its own deadlines, that can work in your favor. You may be able to move straight to external review.
Want your actual deadline, not a general rule? Enter your denial date and we'll estimate your window and flag if you need to act this week.
Calculate my external-review deadline →What documents go in a winning GLP-1 external review packet?
Build your packet around the insurer's exact denial reason — not around how badly you want the medication. At a minimum, include the denial letter, your final appeal denial, the plan's written rules, your prior-authorization and appeal paperwork, a targeted doctor's letter, your BMI and diagnosis history, proof of other health conditions, any diet/exercise records, your medication history, and proof that alternatives don't work for you.
The packet checklist:
- The denial notice and the final appeal denial letter
- Your Explanation of Benefits, insurance card, and plan name
- Your Summary Plan Description / Summary of Benefits and Coverage (SPD/SBC) -- the documents that spell out what your plan covers
- The drug formulary and the plan's clinical rules
- The original prior-authorization request and your internal appeal
- All fax confirmations or portal receipts (proof you submitted on time)
- A doctor's letter, chart notes, and your weight/BMI over time
- Your starting BMI and current BMI
- Other health conditions, with labs that back them up
- A sleep study (if sleep apnea); heart history (if heart risk); a diabetes diagnosis (if Ozempic or Mounjaro)
- Past medications tried, with dates, side effects, or reasons they didn't work
- Diet/exercise or program records (dietitian, clinic, supervised program -- see the cases below on why an app may not count)
- Pharmacy fill history and any prior approvals
- A short call log of every contact with the insurer
Put a one-page summary on top.
List the patient, plan, medication, diagnosis, the denial reason, why the case qualifies for external review, the rules you meet (with proof), the attached evidence, your doctor's contact info, and the deadline. Reviewers read a lot of files. Make yours easy.
What to leave out:
Long emotional statements with no evidence, random screenshots, unproven medical claims, and any suggestion that a compounded GLP-1 medication is the same as an FDA-approved brand. It isn't, and saying so can hurt you.
Copy-and-paste prompt for your doctor:
“Can you write a letter that answers the insurer's exact denial reason and cites the plan's rules? Please include my starting BMI and current BMI, my diagnosis codes, my other health conditions, the weight-loss methods and medications I've already tried, any side effects or reasons they didn't work, and why stopping or switching would be medically wrong for me.”
Want a checklist matched to your specific denial? We'll generate the packet list and the doctor-letter prompt for your exact reason.
Build my external-review packet →What actually wins a GLP-1 external review (real public cases)
New York's Department of Financial Services publishes its external-appeal decisions with names removed. We read through the Wegovy cases and pulled the pattern. These are real, public records — and they show the exact difference between the appeals that won and the ones that lost.
| Case | Drug | Denial reason | Result | Why it went that way |
|---|---|---|---|---|
| 202209-153866 | Wegovy | Not medically necessary | Overturned | On Wegovy ~6 months, lost over 5% of body weight (187 to 163 lbs) and kept it off. Documented results met the rule. |
| 202203-148028 | Wegovy | Not medically necessary | Overturned | Plan required proof of 5%+ weight loss; the doctor documented over 5% in under 3 months (173 to 156 lbs). They answered the exact rule. |
| 202204-148109 | Wegovy | Not medically necessary (supply policy) | Overturned | BMI 40, down 44 lbs over 6 months, on Weight Watchers. Strong results beat a weak denial reason. |
| 202211-155996 | Wegovy | Not medically necessary | Overturned | BMI 28 with high cholesterol and liver disease (NASH); a specialist supported it. A real medical reason carried it. |
| 202303-160505 | Wegovy | Not medically necessary (BMI dropped) | Overturned | Went from BMI 54 to 24.4. The reviewer cited Endocrine Society guidance on continuing treatment after success to prevent regain. |
| 202206-150812 | Wegovy | Not medically necessary (step therapy not met) | Upheld | The doctor said the cheaper drugs were unsafe due to blood pressure, but the records showed the blood pressure was controlled -- so that reason didn't hold. |
| 202305-163087 | Wegovy | Not medically necessary | Upheld | Failed Ozempic and dieted 3 months, but the plan required a supervised, in-office program. A weight-loss app didn't count. |
| 202304-162192 | Wegovy | Not medically necessary | Upheld | The plan caps therapy at 2 years and the patient had reached a normal BMI, so continuing didn't meet the rule. |
| 202306-164131 | Wegovy | Not medically necessary | Upheld | The plan required ongoing participation in a qualifying weight-management program plus in-office monitoring; that wasn't documented. |
Source: New York State Department of Financial Services, public external-appeal database.
The pattern is loud and clear.
The wins all did the same thing: they answered the plan's specific written rule with specific proof — a documented 5% weight loss, a real reason a cheaper drug was unsafe, a covered medical condition, a guideline citation. The losses did the same thing too: they argued “my patient needs this” without the exact proof the rule demanded.
So your job isn't to be more passionate. It's to be more precise. Find the rule. Answer the rule. Attach the proof.
One fair note, straight from the state: New York's DFS says its database is for general information only, every case depends on its own facts, and similar cases can go the opposite way. Use these to learn what reviewers look for — not as a promise about your case.
What if insurance says GLP-1s are “excluded” as weight-loss drugs?
A clean exclusion is the hardest case, because it's about what your plan covers — not whether you need the medicine. Your better moves are to confirm the exclusion is truly absolute, check whether your medication was prescribed for a covered condition beyond weight loss, make sure the plan followed its own process, and ask HR whether anything can change.
An exclusion
The plan doesn't cover this kind of drug at all. Usually not winnable through external review.
A denial
The plan covers this kind of drug but says you didn't qualify. Often winnable.
The covered-diagnosis angle — only if it's genuinely true for you.
Some GLP-1s are FDA-approved for conditions beyond weight loss, and those uses may be covered even when weight-loss use isn't:
- •Ozempic — approved for type 2 diabetes, and to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and known heart disease.
- •Mounjaro — approved for type 2 diabetes in adults (with diet and exercise).
- •Wegovy — approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults with known heart disease who are overweight or obese.
- •Zepbound — approved for moderate-to-severe obstructive sleep apnea in adults with obesity, along with a reduced-calorie diet and more activity.
Never invent a diagnosis — that's fraud and puts your health record at risk. This only works when the condition is real and documented.
A script for HR or your benefits team:
“Can you confirm whether the plan excludes all anti-obesity medications, only weight-loss uses, or only this one drug? If it's an employer choice, who can review whether a medical exception, continuation, or a change at the next plan year is possible?”
A weight-loss exclusion is usually your employer's plan choice — not a law. Many employers are adding this benefit as workers ask for it, so a short, factual note sometimes changes next year's plan.
When to stop appealing and switch paths. If the exclusion is clean and no covered diagnosis applies, it's time to look at other ways to get and afford the medication — covered below.
What if they stopped covering your GLP-1 after you were already on it?
This is one of the most painful denials, and it needs different proof than a first-time request. You'll need your prior approval letters, fill history, your weight and BMI over time, how well it's worked, the plan's current continuation rules, and a doctor's note on why stopping or switching is a medical problem.
The plan says you no longer meet continuation rules
Often winnable — especially if you actually do still meet them. (Remember case 202303-160505 above: denied because BMI dropped, then overturned because guidelines support continuing treatment to prevent regain.)
The plan removed the benefit entirely
That's usually an HR or benefits issue, not an external-review one — go straight to HR or to a backup path.
This is also happening more by design. As GLP-1 costs rise, more employers are adding hurdles — program requirements, tighter rules, or limiting coverage to specific conditions. You didn't do anything wrong. The ground shifted under a lot of people at once.
Coverage pulled after you were already on it? We'll help you build a continuation packet aimed at your plan's exact rules.
Build a continuation-of-coverage packet →Should you ask for an expedited (urgent) external review?
Ask for an expedited review only when waiting the standard time would seriously threaten your health or your ability to function — and have your doctor back it up with specifics. Done right, you can get a decision in as little as 72 hours.
What counts as urgent is a real medical standard — serious risk to your health, not frustration or inconvenience. Your doctor's urgency letter should name your diagnosis, your current medication status, the specific harm from stopping, and why 45 days is too long to wait.
Don't overstate it.
Claiming urgency you can't back up can hurt your credibility with the reviewer. If it's genuinely urgent, say so clearly and let your doctor document why.
Think your case might be urgent? We'll help you see if it fits the expedited standard before you ask.
See if my case fits expedited review →Who handles your external review: state, federal, employer plan, Medicare, or Medicaid?
Your final denial letter tells you where to file — read it first. Filing in the wrong place wastes days you may not have. Here's how to tell which one is yours.
| Plan type | How to tell | Where the review goes | What document controls | Common mistake |
|---|---|---|---|---|
| Plan you bought / ACA Marketplace | You buy it directly or through the Marketplace | Your state's external-review program (often via the state Department of Insurance) | Your final denial letter | Filing late — the deadline is on the letter |
| Fully-insured employer plan | Employer offers it; an insurer pays the claims | Usually your state's external-review program | Denial letter + your SBC | Assuming it's self-funded when it isn't |
| Self-funded employer plan (often “ERISA”) | Your plan documents say “self-funded” or “self-insured” | A federal external-review route — the HHS-administered process (run by MAXIMUS Federal Services) or an accredited IRO the plan uses | Denial letter + Summary Plan Description | Filing with your state, which usually can't help with a self-funded plan |
| Medicare | You have Medicare Part A/B/D or a Medicare Advantage plan | Medicare's own multi-level appeals — not the ACA external review on this page | Your Medicare denial notice | Using the ACA external-review steps by mistake |
| Medicaid | State Medicaid or a Medicaid managed-care plan | Your state's fair-hearing process | Your state Medicaid notice | Missing the state fair-hearing deadline |
Source: HealthCare.gov; CMS; U.S. Department of Labor. Not sure if your employer plan is self-funded? Ask HR or check your plan documents.
A note for Medicare and Medicaid readers.
Medicare and GLP-1s work differently. Medicare Part D cannot cover a GLP-1 prescribed only for weight loss — that's a federal rule — though it can cover one for diabetes, heart-risk reduction, or sleep apnea when the diagnosis fits. One change to know: starting July 1, 2026, a temporary Medicare GLP-1 Bridge is set to cover Foundayo, Wegovy (pill and injection), and the Zepbound KwikPen for weight loss for eligible Part D members for a $50 monthly copay, running through December 31, 2027 ( CMS; the single-dose Zepbound vial and pen are not included, and the $50 copay doesn't count toward your Part D out-of-pocket cap). For a Medicare denial, use your Medicare notice for the right steps — not the ACA steps above.
For Medicaid GLP-1 coverage, use your state's fair-hearing process — not ACA external review.
Not sure who reviews your case? We'll point you to the right filing route based on your plan type and state.
Find my filing route →What if your external review is denied?
If the external review goes against you, your next move depends on why it failed. Don't keep re-filing the same losing argument — match your situation to the table below.
| Why it failed | What it means | Your next move | Who to contact |
|---|---|---|---|
| The reviewer agreed with the plan's rules | The clinical call went against you on the record | Ask if new evidence, a new diagnosis, or different rules reopen it | Your prescriber; the plan |
| It's a true plan exclusion | The benefit isn't there to win | Push for a covered diagnosis, or ask HR to add the benefit | HR / benefits; your prescriber |
| The plan mishandled the process | A procedural error may give you new options | Raise it with a regulator | EBSA (employer plans) or your state Department of Insurance |
| You need the medication now | The appeal path is closed for the moment | Compare covered-diagnosis, manufacturer-savings, and cash-pay options | Your prescriber; see below |
Out of appeal options? We'll lay out your realistic backup paths side by side.
Compare my backup GLP-1 access paths →Which GLP-1 path should you use while your review is pending?
If your case is strong and you can safely wait, focus on filing it right before changing anything. If your coverage is already gone and the gap is a real problem, you can look at other routes while your doctor advises on staying on treatment. Here are the honest options, in plain terms.
1) Keep fighting the insurance path
If you have a commercial plan, the drug is covered in general, you may meet the rules, your deadline is open, and your doctor will back you. This is usually the cheapest outcome — many covered patients pay a small copay. See GLP-1 appeal levels explained for the full path from denial to external review.
2) Run a free coverage check
If you're on a commercial plan and want to know exactly what you're working with before you spend more energy, Ro publishes a free GLP-1 Insurance Coverage Checker. It contacts your insurer and sends back a personalized report: whether each GLP-1 is covered, whether prior authorization is required, and your estimated cost. New accounts also get a $50 credit. It's useful even if you never sign up for Ro.
| Ro says | What we verified (June 3, 2026) | The catch |
|---|---|---|
| Free GLP-1 Insurance Coverage Checker, plus a $50 credit for new accounts | Live on ro.co; returns a coverage, prior-auth, and cost report | You enter your insurance details to run it |
| Insurance concierge files prior authorizations and helps with denials | Confirmed on ro.co; about 2-3 weeks when using insurance | Works with commercial plans and FEHB only |
| FDA-approved brand-name GLP-1s (Wegovy pen and pill, Zepbound, Foundayo, Ozempic) | Confirmed product pages live on ro.co | Brand-name only; no compounded blurring |
| Membership: $39 first month, then $149/mo, or as low as $74/mo with an annual plan paid upfront | Matches Ro's current pricing page | Medication is billed separately |
| Can't coordinate government insurance | Confirmed: the concierge is commercial + FEHB; Ro can't bill Medicare, Medicaid, or TRICARE | Medicare or TRICARE members may still join and pay cash; Medicaid members generally can't use Ro |
One honest limitation — please read.
Ro's coverage help is for commercial insurance (FEHB accepted). It cannot coordinate coverage with Medicare, Medicaid, or TRICARE. If you're on a government plan, the coverage checker can't help your appeal — use the Medicare or Medicaid steps above instead.
Disclosure: The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. The Ro link below is an affiliate link, which means we may earn a commission if you use it — at no extra cost to you. Our Ro recommendation here is based on the insurance-sensitive, FDA-approved fit described above.
On a commercial plan and want your coverage facts before you fight?
Check my GLP-1 coverage free with Ro →Best for commercial-insurance members who want a branded-medication coverage report.
3) Cash-pay for an FDA-approved brand
If insurance won't cover it and you want to stay on an FDA-approved medication, some telehealth programs offer transparent cash-pay prices for brand-name GLP-1s. Compare prices the day you buy, since they change.
4) A word on compounded medications
You'll see cheaper compounded GLP-1s advertised. Be clear-eyed: compounded GLP-1 medications are not FDA-approved finished drugs. They are not interchangeable with FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro. And the legal room for them has narrowed: the semaglutide and tirzepatide shortages have ended, and on April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk ingredients that large outsourcing pharmacies may compound, finding no clinical need when FDA-approved versions are available ( FDA). That proposal is open for public comment, not yet final — but the direction is clear. If you consider a compounded option, do it with your eyes open and your doctor in the loop.
Still not sure which path fits you?
Take our free 60-second matching quiz and get a personalized action plan for your situation.
Get my personalized GLP-1 action plan →How we built this guide (and what we did — and didn't — verify)
We made this as a plain-English insurance-help guide, built on primary government sources, real public external-review decisions, and verified provider facts.
What we verified on :
- •Federal external-review deadlines and decision timelines (HealthCare.gov; CMS)
- •Which denials qualify for external review (HealthCare.gov; CMS)
- •The 180-day internal-appeal window (HealthCare.gov)
- •Real, public Wegovy external-appeal outcomes (New York DFS database)
- •National denial and appeal rates, and how many people know their appeal rights (KFF)
- •California's external-review timelines and ~73% reversal figure (California DMHC)
- •The Medicare GLP-1 Bridge drugs, copay, and dates (CMS)
- •The FDA's April 30, 2026 proposal on compounded GLP-1s (FDA)
- •Ro's free coverage checker, concierge, pricing, and government-plan limits (Ro)
What we could NOT verify for your specific case:
- •Your plan's exact formulary and rules
- •Your employer's benefit design
- •Your state's exact deadline (verify on your letter and your state Department of Insurance)
- •Whether your doctor will write a letter
- •Whether your appeal will win
- •The specific Medicare or Medicaid steps for your plan
FAQ: external review for a GLP-1 insurance denial
Is external review the same as an insurance appeal?
No. An internal appeal asks your insurer to reconsider its own decision. An external review hands the case to an independent outside expert whose decision is binding on the plan. External review usually comes after your internal appeal is denied.
Do I have to finish internal appeals before external review?
Usually yes. But if your case is urgent you can often request an expedited external review at the same time, and if your insurer misses its own deadlines you may be able to go straight to external review.
How long do I have to request external review for a GLP-1 denial?
Generally 4 months after you receive your final denial notice under federal rules, though your state may allow more or less. The deadline on your denial letter is the final word, so don't wait.
How long does an external review take?
A standard decision is due within 45 days under federal rules (30 days in California). Urgent cases can be decided within 72 hours (7 days in California).
Is an external review decision binding on my insurer?
Yes. If the reviewer overturns the denial, the plan must cover the treatment. In California, the plan must authorize it within 5 business days.
Can external review overturn a not medically necessary denial?
Yes -- that is one of its strongest uses. The key is answering the plan's specific written rules with specific proof from your records, as the real overturned cases on this page show.
What if my plan excludes weight-loss drugs?
External review usually cannot override a clean exclusion, because it is a coverage choice rather than a medical decision. Check whether a covered diagnosis applies, ask HR, or look at a cash-pay path.
Can external review help if I was already taking Wegovy or Zepbound and got cut off?
Often yes, if you still meet the plan's continuation rules. You will need your prior approvals, your results over time, and a doctor's note. If the benefit was removed entirely, that is an HR issue, not an external-review one.
Can my doctor file the external review for me?
You or your authorized representative can file, and your doctor's documentation is central to the case. Check your letter for who must sign and how to submit.
Do I need a lawyer for a GLP-1 external review?
Most people do not. External review is free and built for patients to use. A lawyer or patient advocate can help with complex cases or possible bad-faith denials.
Does external review apply to Medicare or Medicaid?
No -- those use separate appeal systems. Medicare has a multi-level process and Medicaid uses your state's fair-hearing process. This page is mainly for commercial and private insurance.
What should I do if the external review is denied?
It depends on why. You may request your plan documents, contact a regulator, ask HR about the benefit, or move to a covered diagnosis or an affordable cash-pay route. See the table in the guide above.
Still deciding?
Insurance denials are built to be exhausting. You don't have to figure this out alone, and you don't have to guess.
Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.
Find my personalized GLP-1 action plan →The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some links on this page are affiliate links; we may earn a commission if you use them, at no extra cost to you. This page is educational and is not medical or legal advice. A licensed clinician decides whether any GLP-1 medication is right for you, and your plan documents decide your benefits.
Sources
- •HealthCare.gov — External Review and Internal Appeals
- •CMS — HHS-Administered Federal External Review Process
- •eCFR — 45 CFR §147.136 (internal claims, appeals, and external review)
- •U.S. Department of Labor (EBSA) — Filing a Claim for Your Health Benefits
- •KFF — Claims Denials and Appeals in ACA Marketplace Plans in 2024
- •California DMHC — Independent Medical Review FAQ
- •New York State DFS — Public external-appeal database
- •CMS — Medicare GLP-1 Bridge, information for beneficiaries
- •FDA — Proposal to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- •Ro — GLP-1 Insurance Coverage Checker